Figure 6.
Neutralizing Antibody Response after VesG-LV Administration
Neutralizing activities of (A) CO-COCV.G, (B) CO-MARAV.G, and (C) CO-PIRYV.G sera isolated from terminal bleeds. (D) Neutralizing activity of IC-COCV.G, IC-MARAV.G, and IC-PIRYV.G sera isolated from terminal bleeds against their respective pseudotypes. (E) Neutralizing activity of IC-VesG sera isolated from terminal bleeds against VSVind.G-LV compared to the neutralizing activity observed after s.c. Gth immunization. Solid lines signify the neutralization effect observed, while the dotted lines indicate the lack of neutralization. The calculated IC50 values were as follows: immunization only, 7.15 × 10−3; COCV, 5.21 × 10−3; MARAV, 2.49 × 10−3; PIRYV, 1.90 × 10−2; and VSVind, 1.52 × 10−4. Data shown represent the mean ± SD of three repeats performed in duplicates. (F) Anti-PIRYV.G antibodies produced following PIRYV.G-LV challenge of non-immunized (CO) and pre-immunized (IC) mice. One-way ANOVA followed by Tukey’s multiple comparison post-test was performed to analyze the significance of the amount of anti-PIRYV.G antibodies produced (****p < 0.0001). Data shown represent mean ± SD from two experiments performed in duplicates. (G) Table summarizing measured IC50 values of the observed neutralizing activity of CO- and IC-VesG sera. All neutralization experiments were performed as outlined in the Materials and Methods following sera adsorption to HEK293T cells. To calculate IC50 values, curves were fitted using the software GraphPad Prism 5 modeled as an [inhibitor] versus response curve with variable hill slopes.